Yildirim, H. C. Et Al. 2024. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study. Journal of Chemotherapy .

Yildirim, H. C., Kapar, C., KÖKSAL, B., Seyyar, M., Sanci, P. C., Guliyev, M., ... Perkin, P.(2024). Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study. Journal of Chemotherapy .

Yildirim, Hasan Et Al. "Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study," Journal of Chemotherapy , 2024

Yildirim, Hasan C. Et Al. "Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study." Journal of Chemotherapy , 2024

Yildirim, H. C. Et Al. (2024) . "Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study." Journal of Chemotherapy .

@article{article, author={Hasan Cagri Yildirim Et Al. }, title={Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study}, journal={Journal of Chemotherapy}, year=2024}